Publication details
Zhodnocení profilu dabigatran etexilátu z pohledu dosavadních studií zaměřených na prevenci žilní trombózy v ortopedických indikacích
| Title in English | Evaluation of dabigatran etexilate profile in view of previous studies on the prevention of venous thrombosis in orthopedic indications |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Ortopedie |
| MU Faculty or unit | |
| Citation | |
| Field | Other medical specializations |
| Keywords | dabigatran; antithrombotic prophylaxis |
| Description | Dabigatran etexilate is one of the new options of antithrombotic prophylaxis and therapy. Moreover, it is an oral treatment with the possibility of administration not requiring laboratory monitoring of its effect. It has been the subject of many clinical trials focused on the efficacy and safety in patients after total hip/knee replacement surgery. From an orthopaedic point of view the RE-NOVATE II study, which compares the efficacy and safety of oral dabigatran 220mg once a day versus subcutaneous enoxaparin 40mg once a day for extended thromboprophylaxis in patients undergoing total hip arthroplasty, is one of the most important trials in this field. The trial has shown the same efficacy of oral dabigatran and enoxaparin in reducing venous thromboembolism and all-causes death (primary endpoint), and superiority of dabigatran vs. enoxaparin in reducing the risk of major VTE and VTE-related mortality (secondary endpoint), and comparable risk of bleeding. |